Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1986 1
1987 2
1988 3
1989 2
1990 1
1992 2
1993 4
1994 6
1995 6
1996 18
1997 15
1998 7
1999 9
2000 19
2001 5
2002 9
2003 7
2004 12
2005 17
2006 18
2007 14
2008 13
2009 20
2010 11
2011 14
2012 25
2013 18
2014 14
2015 21
2016 28
2017 26
2018 23
2019 22
2020 18
2021 23
2022 29
2023 22
2024 11
2025 1

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

458 results

Results by year

Filters applied: . Clear all
Page 1
[177Lu]Lu-DOTA-TATE plus long-acting octreotide versus high‑dose long-acting octreotide for the treatment of newly diagnosed, advanced grade 2-3, well-differentiated, gastroenteropancreatic neuroendocrine tumours (NETTER-2): an open-label, randomised, phase 3 study.
Singh S, Halperin D, Myrehaug S, Herrmann K, Pavel M, Kunz PL, Chasen B, Tafuto S, Lastoria S, Capdevila J, García-Burillo A, Oh DY, Yoo C, Halfdanarson TR, Falk S, Folitar I, Zhang Y, Aimone P, de Herder WW, Ferone D; all the NETTER-2 Trial Investigators. Singh S, et al. Among authors: de herder ww. Lancet. 2024 Jun 29;403(10446):2807-2817. doi: 10.1016/S0140-6736(24)00701-3. Epub 2024 Jun 5. Lancet. 2024. PMID: 38851203 Clinical Trial.
Correction: Methodology of the SORENTO clinical trial: a prospective, randomised, active-controlled phase 3 trial assessing the efficacy and safety of high exposure octreotide subcutaneous depot (CAM2029) in patients with GEP-NET.
Singh S, Ferone D, Capdevila J, Chan JA, de Herder WW, Halperin D, Mailman J, Hellström L, Liedman H, Svedberg A, Tiberg F. Singh S, et al. Among authors: de herder ww. Trials. 2024 May 2;25(1):297. doi: 10.1186/s13063-024-08146-1. Trials. 2024. PMID: 38698434 Free PMC article. No abstract available.
Glucagon and insulin: 100 years young.
de Herder WW, Klöppel G. de Herder WW, et al. Endocr Relat Cancer. 2024 Apr 16;31(5):e230345. doi: 10.1530/ERC-23-0345. Print 2024 May 1. Endocr Relat Cancer. 2024. PMID: 38631379 No abstract available.
Management of patients with rare adult solid cancers: objectives and evaluation of European reference networks (ERN) EURACAN.
Blay JY, Casali P, Ray-Coquard I, Seckl MJ, Gietema J, de Herder WW, Caplin M, Klümpen HJ, Glehen O, Wyrwicz L, Peeters R, Licitra L, Girard N, Piperno-Neumann S, Kapiteijn E, Idbaih A, Franceschi E, Trama A, Frezza AM, Hohenberger P, Hindi N, Martin-Broto J, Schell J, Rogasik M, Lejeune S, Oliver K, de Lorenzo F, Weinman A. Blay JY, et al. Among authors: de herder ww. Lancet Reg Health Eur. 2024 Feb 16;39:100861. doi: 10.1016/j.lanepe.2024.100861. eCollection 2024 Apr. Lancet Reg Health Eur. 2024. PMID: 38384730 Free PMC article. Review.
Methodology of the SORENTO clinical trial: a prospective, randomised, active-controlled phase 3 trial assessing the efficacy and safety of high exposure octreotide subcutaneous depot (CAM2029) in patients with GEP-NET.
Singh S, Ferone D, Capdevila J, Chan JA, de Herder WW, Halperin D, Mailman J, Hellström L, Liedman H, Svedberg A, Tiberg F. Singh S, et al. Among authors: de herder ww. Trials. 2024 Jan 16;25(1):58. doi: 10.1186/s13063-023-07834-8. Trials. 2024. PMID: 38229199 Free PMC article. Clinical Trial.
458 results